T-3764518, as a new oral SCD1 inhibitor, can alter lipid metabolism by disrupting the balance of saturated and unsaturated fatty acid in membrane lipid, thus playing an anti-tumor role in vivo and in vitro (Nishizawa et al., 2017). This evidence concerns the gene SCD and neoplasm.